c-kit Stem Cell Therapy of Ischemic Cardiomyopathy
|
|
- Norman Greene
- 6 years ago
- Views:
Transcription
1 American Heart Association Scientific Sessions American Heart Association Scientific Sessions c-kit Stem Cell Therapy of Ischemic Cardiomyopathy Roberto Bolli, M.D. Institute of Molecular Cardiology University of Louisville Los Angeles, CA
2 Presenter Disclosure information Roberto Bolli, M.D. c-kit Stem Cell Therapy of Ischemic Cardiomyopathy FINANCIAL DISCLOSURE: None UNLABELED/UNAPPROVED USES DISCLOSURE: None
3 Publius Cornelius Scipio Africanus ( BC) SCIPIO (Study of Cardiac Stem Cells Infusion in Patients with Ischemic CardiOmyopathy) Phase I, open-label, randomized trial Single center 20 treated and 13 control patients
4 SCIPIO (Study of Cardiac Stem Cells Infusion in Patients with Ischemic CardiOmyopathy) Institute of Molecular Cardiology Brigham and Women s Hospital John Loughran Brandon Elmore Marcus Stoddard Garth Beache Atul Chugh Sohail Ikram Steve Wagner Piero Anversa Annarosa Leri Jan Kajstura Domenico D Amario
5 SCIPIO: Objectives The overall goal is to translate the discovery of CSCs into clinically useful therapies. Primary Objective 1. To assess the feasibility and safety of infusing autologous c-kit pos CSCs in patients with ischemic heart failure. Secondary Objective 2. To obtain preliminary evidence for or against the efficacy of CSCs in augmenting LV function, improving functional status, and promoting myocardial regeneration.
6 SCIPIO: Time Line A result of many years of preclinical work: FDA contacted in October 2004 FDA approval on August 8, 2008 First patient enrolled on March 13, 2009 Last Patient Enrolled May 17, IND application submitted on January 2006 Trial opened to enrollment in February 2009 First CSC infusion July 17, 2009
7 November 14, 2011
8 SCIPIO Inclusion Criteria LVEF 40% A history of Q-wave MI with a residual scar (as evidenced by ECG, cardiac MRI, low-dose dobutamine stress echo, and/or rest perfusion images on a sestamibi SPECT study) Patient scheduled for CABG within 2 weeks of the initial screening.
9 SCIPIO: Protocol < 2 Weeks Enrollment CABG & Tissue Harvesting At the time of CABG, the right atrial appendage is resected and prepared for CSC isolation CSC isolation and expansion
10 SCIPIO: Protocol < 2 Weeks 4 ± 1 Months 2 Years Enrollment CABG & Tissue Harvesting CSC Infusion Follow-Up Cardiac MRI 2-D & 3-D Echo ECG, Physical Exam BMP, LFTs, CBC, and BNP Minnesota Heart Questionnaire and NYHA class assessment
11 SCIPIO: Protocol 2-D & 3-D Echo 24-h Holter monitor ECG BMP & LFTs CBC, & cardiac enzymes Physical Exam 2-D & 3-D Echo Cardiac MRI ECG, Physical Exam BMP, LFTs, CBC, and BNP Minnesota Heart Questionnaire and NYHA class assessment CSC Rx Follow-up 24h Week 1 Week 2 Week 4 Month 4 ECG x 3 BMP, LFTs CBC Cardiac enzymes x 3 Physical exam ECG BMP, LFTs CBC Cardiac enzymes Physical exam 2-D & 3-D Echo 24-h Holter monitor ECG BMP & LFTs CBC, & cardiac enzymes Physical Exam
12 SCIPIO: Protocol 2-D & 3-D Echo Cardiac MRI ECG, Physical Exam BMP, LFTs, CBC, and BNP Minnesota Heart Questionnaire and NYHA class assessment CSC Rx Follow-up Month 8 Year 1 Year 2 ECG BMP, LFTs CBC 2-D & 3-D Echo Cardiac MRI ECG, Physical Exam BMP, LFTs, CBC, and BNP Minnesota Heart Questionnaire and NYHA class assessment
13 SCIPIO Phenotype of CSCs
14 SCIPIO: Phenotype of CSCs
15 SCIPIO: Phenotype of CSCs
16 SCIPIO Phenotype of CSCs
17 SCIPIO: Phenotype of CSCs
18 SCIPIO: Phenotype of CSCs
19 SCIPIO: Phenotype of CSCs
20 SCIPIO: Phenotype of CSCs Telomere Length
21 Absolute EF Units SCIPIO: Results Ejection Fraction at 4 Months After CSCs 60 P= ± ± ± ± Baseline 4 months Controls (n=7) Pre-CSC 4 months CSC-treated (n=14)
22 Absolute EF Units SCIPIO: Results Change in Ejection Fraction After CSC Treatment n=14 n= P= ±2.0 P< ± months 12 months
23 Absolute EF units SCIPIO: MRI Results Ejection Fraction (MRI) After CSC Therapy n=8 n=8 n=5 Pre-CSC P=0.004 P= months 12 months 41.2
24 ΔEF (absolute EF units) SCIPIO: MRI Results Change in Ejection Fraction (MRI) After CSC Therapy 25 n=8 n=5 Baseline EF: 27.5% 20 P= ± P= ± months 12 months
25 Absolute EF units ΔEF (absolute EF units) SCIPIO: MRI Results Regional Ejection Fraction in Infarct-Related Segments After CSC Therapy 80 n=8 n=8 n=5 40 n=8 n= P= ±3.9 P= ± Pre-CSC 4 months 12 months 4 months 12 months
26 Absolute EF units SCIPIO: MRI Results Regional Ejection Fraction (MRI) in Infarct- Related Segments After CSC Therapy 40 P=0.008 n=8 50 P=0.085 n= ± ± ± ± Pre-CSC 4 months Pre-CSC 12 months
27 Absolute EF units ΔEF (absolute EF units) SCIPIO: MRI Results Regional Ejection Fraction in Dyskinetic Segments After CSC Therapy 40 n=7 n=7 n=4 80 n=7 n= P= ±7.1 P= ± Pre-CSC 4 months 12 months 4 months 12 months
28 Absolute EF units ΔEF (absolute EF units) SCIPIO: MRI Results Regional Ejection Fraction in the Least Functional Segment After CSC Therapy n=8 n=8 n= n=8 P= ±8.5 n=5 P= ± Pre-CSC 4 months 12 months 0 4 months 12 months
29 SCIPIO: Results Global Wall Motion Score Index 4 Months After CSC Treatment 3.0 P= Baseline 4 months Controls (n=7) Pre-CSC 4 months CSC-treated (n=14)
30 SCIPIO: Results Global WMSI After CSC Treatment in Patients Who Have Completed 12 Month Follow-up 5 n=8 4 P= ±0.08 P= ± ± Pre-CSC 4 months 12 months
31 SCIPIO: Infarct Regression Before CSCs 24 months after CSCs
32 Mass (g) Change in mass (g) SCIPIO: MRI Results Change in Infarct Size by CMR Using a Semiautomated (FWHM) Method After CSC Treatment 50 n=9 n=9 n= Pre-CSC months 12 months P< ± % n=9 P= ± % n=6 4 months 12 months
33 Mass (g) Change in mass (g) SCIPIO: MRI Results Change in Non-Viable Tissue by CMR After CSC Treatment n=9 n=9 n= Pre-CSC months 12 months ±2.5 P= % -14.8±3.9 P= % n=9 n=6 4 months 12 months
34 Mass (g) Change in mass (g) SCIPIO: MRI Results Change in Viable Tissue by CMR After CSC Treatment n=9 n=9 n= n=9 n=6 7.6% 11.6±5.2 P= % 31.5±11.0 P= Pre-CSC 4 months 12 months 0 4 months 12 months
35 SCIPIO: Results 4 New York Heart Association Score 4 Months After CSC Treatment 3 P=0.172 P= ± ± ± ± Baseline 4 months Controls (n=7) Pre-CSC 4 months CSC-treated (n=16)
36 SCIPIO: Results NYHA Score After CSC Treatment in Patients Who Have Completed 12 Month Follow-up 6 5 P=0.004 n=10 4 P= ± ± ± Pre-CSC 4 months 12 months
37 SCIPIO: Results MLHFQ Score 4 Months After CSC Treatment ± ± ±5.2 P< ± Baseline 4 months Pre-CSC 4 months Controls (n=7) CSC-treated (n=16)
38 SCIPIO: Results MLHFQ After CSC Treatment in Patients Who Have Completed 12 Month Follow-up ±7.5 P<0.001 P=0.007 n= ± ± Pre-CSC 4 months 12 months
39 SCIPIO: Summary i) Feasibility and safety The initial results of SCIPIO indicate that, in patients with ischemic cardiomyopathy: 1. Isolation, expansion, and infusion of a highly pure population of c-kit pos CSCs are feasible in virtually all cases. 2. It is possible to obtain viable CSCs with high telomerase activity and telomeres >7 kbp. 3. Intracoronary infusion of autologous CSCs is not associated with appreciable adverse effects.
40 SCIPIO: Summary ii) Efficacy The initial results of SCIPIO indicate that: 4. Infusion of CSCs results, 4 months later, in a reduction in infarct size, an increase in viable myocardium, and a marked improvement in LV EF, NYHA functional class, and quality of life (MLHFQ). 5. These effects persist and are even more pronounced at 1 year.
41 SCIPIO: Conclusions The initial results of SCIPIO suggest that administration of autologous c-kit pos CSCs is feasible and safe and produces a sustained increase in viable myocardium, LV systolic function, and functional capacity in patients with ischemic cardiomyopathy. Larger, Phase II studies are warranted.
42 Acknowledgments Xian-Liang Tang Yiru Guo Gregg Rokosh Qianghong Li Institute of Molecular Cardiology Atul Chugh John Loughran Sohail Ikram Marcus Stoddard Steve Wagner Garth Beache Mark Slaughter Boston group Piero Anversa Annarosa Leri Jan Kajstura
43 Thank You
Domenico D Amario MD, PhD Università Cattolica del Sacro Cuore Rome:
Domenico D Amario MD, PhD Università Cattolica del Sacro Cuore Rome: 31.01.2014 (Rosamund et al, Circulation 2007) Discharges in Thousands Hospital discharges for heart failure by sex (United States: 1979-2004).
More informationA Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)
A Light in the Dark: Cardiac MRI and Risk Mitigation J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) Dr. Mikolich has NO financial disclosures relative to
More informationRational use of imaging for viability evaluation
EUROECHO and other imaging modalities 2011 Rational use of imaging for viability evaluation Luc A. Pierard, MD, PhD, FESC, FACC Professor of Medicine Head, Department of Cardiology, CHU Liège, Belgium
More information3/27/2014. Introduction.
Introduction. Myocardial perfusion & contractility becomes abnormal immediately after the onset of ischaemia, even before the development of the symptoms & ST segment changes. 1 Myocardial Wall Motion
More informationENDOGENOUS CARDIAC STEM CELLS IN THE REGENERATION OF ACUTE AND CHRONIC ISCHEMIC MYOCARDIUM
ENDOGENOUS CARDIAC STEM CELLS IN THE REGENERATION OF ACUTE AND CHRONIC ISCHEMIC MYOCARDIUM Bernardo Nadal-Ginard, M.D., Ph.D. New York Medical College Angioplasty Summit 2004, Seoul 04/29/04 MYOCARDIAL
More informationA Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)
A Light in the Dark: Cardiac MRI and Risk Mitigation J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) Dr. Mikolich has NO financial disclosures relative to
More informationDr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK
Advanced heart failure - devices, mechanical circulatory support and cardiac transplantation Monday 30 January 2017 Stem cell and gene therapies for heart failure Dr. Alexander Lyon Senior Lecturer and
More informationCell Combination Therapy. Disclosures
Cell Combination Therapy Joshua M. Hare, M.D. Louis Lemberg Professor Senior Associate Dean Chief Science Officer Interdisciplinary Stem Cell Institute The Miller School of Medicine, University of Miami
More informationStable Angina: Indication for revascularization and best medical therapy
Stable Angina: Indication for revascularization and best medical therapy Cardiology Basics and Updated Guideline 2018 Chang-Hwan Yoon, MD/PhD Cardiovascular Center, Department of Internal Medicine Bundang
More informationCardiovascular Imaging Stress Echo
Cardiovascular Imaging Stress Echo Theodora A Zaglavara, MD, PhD Cardiac Imaging Department INTERBALKAN MEDICAL CENTER Thessaloniki GREECE Evolution of Stress Echo: From Innovation to a Widely Established
More informationTranslating Molecular Insights Into New Cellular Therapies For Cardiovascular Disease
Ottawa Hospital Research Institute Institute de recherche de l Hopital d Ottawa Translating Molecular Insights Into New Cellular Therapies For Cardiovascular Disease ACC Rockies March 11-14, 2012 Dr. Duncan
More informationNew and Promising Management Strategies for Heart Failure, 2013
New and Promising Management Strategies for Heart Failure, 2013 Including Highlights from 2012 Heart Failure Society of America, September 2012 and Symposium on Cardiovascular Regeneration Integrated Regenerative
More informationNUCLEAR CARDIOLOGY UPDATE
Nuclear Cardiology David K. Shelton, Jr., MD NUCLEAR CARDIOLOGY UPDATE No Conflicts. No Disclosures. No Smoking. David K. Shelton UCDMC Nuclear Cardiology Nuclear Cardiology Radionuclide Ventriculography
More information1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and
1 The clinical syndrome of heart failure in adults is commonly associated with the etiologies of ischemic and non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease,
More informationCoronary Revascularization in Patients witj Severe LV Dysfunction.: Is the concept of viability still viable?
Coronary Revascularization in Patients witj Severe LV Dysfunction.: Implications of the STICH trial Is the concept of viability still viable? Banff 2016 3041435-1 Prognosis of Patients With LV Dysfunction
More informationEcho in CAD: Wall Motion Assessment
Echo in CAD: Wall Motion Assessment Joe M. Moody, Jr, MD UTHSCSA and STVHCS October 2007 Relevant References ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography Bayes de
More informationSummary Protocol ISRCTN / NCT REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6
Summary Protocol REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6 Background: Epidemiology In 2002, it was estimated that approximately 900,000 individuals in the United Kingdom had a diagnosis
More informationEvaluation of Myocardial Viability: What Have We Learned from STICH? Professor of Medicine David Geffen School of Medicine at UCLA. Heart Failure (HF)
Evaluation of Myocardial Viability: What Have We Learned from STICH? Daniel S. Berman, MD Director, Cardiac Imaging Cedars-Sinai Heart Institute CSMC 2013 Professor of Medicine David Geffen School of Medicine
More informationPrevious MI with no intervention
Previous MI with no intervention F. Mut, M. Beretta Nuclear Medicine Service, Asociacion Española Montevideo, Uruguay Clinical history Woman 68 y.o. Recent acute MI (3 weeks) with no intervention. Discharged
More informationThe prevalence of heart failure (HF) in industrialized
Administration of Cardiac Stem Cells in Patients With Ischemic Cardiomyopathy: The SCIPIO Trial Surgical Aspects and Interim Analysis of Myocardial Function and Viability by Magnetic Resonance Atul R.
More informationAcute Myocarditis Mimicking ST-segment Elevation Myocardial Infarction: Relation Between ECG Changes And Myocardial Damage As Assessed By CMR
Acute Myocarditis Mimicking ST-segment Elevation Myocardial Infarction: Relation Between ECG Changes And Myocardial Damage As Assessed By CMR G. Nucifora 1, A. Di Chiara 2, D. Miani 1, G. Piccoli 3, M.
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationSung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center
CMR Perfusion and Viability A STICH Out of Time? Sung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center Can Imaging Improve
More informationUse of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users
Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users February 1 5, 2011 University of Santo Tomas Hospital Angelo King A-V Auditorium Manila,
More informationMR Assessment of Myocardial Viability
MR Assessment of Myocardial Viability Definition of Viability Clinical Metabolism: Presence of glucose uptake Perfusion / Perfusion reserve Morphology: Wall thickness, wall thickening Contractility: Recovery
More informationHigh Risk PCI for Heart Failure
High Risk PCI for Heart Failure Ray Matthews MD Professor of Clinical Medicine Chief, Division of Cardiovascular Medicine University of Southern California Los Angeles, California Disclosures Abiomed Research
More informationAssessment of Ischemia and Viability
EAE Teaching Course Bucharest, 2010 Assessment of Ischemia and Viability Jens-Uwe Voigt Dpt. of Cardiology University Leuven Belgium Assessment of Ischemia & Viability resting wall motion Stress Testing
More informationMultiple Gated Acquisition (MUGA) Scanning
Multiple Gated Acquisition (MUGA) Scanning Dmitry Beyder MPA, CNMT Nuclear Medicine, Radiology Barnes-Jewish Hospital / Washington University St. Louis, MO Disclaimers/Relationships Standard of care research
More informationRadiologic Assessment of Myocardial Viability
November 2001 Radiologic Assessment of Myocardial Viability Joshua Moss, Harvard Medical School Year III Patient EF 66yo female with a 3-year history of intermittent chest pain previously relieved by sublingual
More informationI have no financial disclosures
Manpreet Singh MD I have no financial disclosures Exercise Treadmill Bicycle Functional capacity assessment Well validated prognostic value Ischemic assessment ECG changes ST segments Arrhythmias Hemodynamic
More informationTypical chest pain with normal ECG
Typical chest pain with normal ECG F. Mut, C. Bentancourt, M. Beretta Nuclear Medicine Service, Asociacion Española Montevideo, Uruguay Clinical history Male 41 y.o. Overweight, hypertension, high cholesterol,
More informationStem Cells. Keith Channon. Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford
Stem Cells Keith Channon Department of Cardiovascular Medicine University of Oxford John Radcliffe Hospital, Oxford Adult Stem Cells Unique cells that are capable of self-renewal Have the ability to differentiate
More informationImaging and heart failure
Imaging and heart failure Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston, St Jude, BMS imaging, GE Healthcare,
More informationWIEF-AFF ROUNDTABLE Tokyo, Japan 26 May 2015
WIEF-AFF ROUNDTABLE 2015 Tokyo, Japan 26 May 2015 Regenerative Medicine Goal: - To restore organ +/- tissue function - For pts with serious injuries or chronic disease where the body unable to heal & restore
More informationCan point of care cardiac biomarker testing guide cardiac safety during oncology trials?
Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University
More informationpresenters 2010 Sameh Sabet Ain Shams University
Guidelines for PCI in late STEMI presenters 2010 Sameh Sabet Assistant Professor of Cardiology Ain Shams University 29% of MI patients have STEMI. NRMI 4 (Fourth National Registry of Myocardial Infarction),
More informationStem cell therapy aimed at restoring organ function,
The : Insights and Lessons From Clinical Trials Kartik S. Telukuntla, BS; Viky Y. Suncion, MD; Ivonne H. Schulman, MD; Joshua M. Hare, MD Stem cell therapy aimed at restoring organ function, notably myocardial
More informationInsights into Viability- Function and Contractile Reserve
Insights into Viability- Function and Contractile Reserve Tom Marwick Cleveland Clinic Conflicts research grants and consulting with GE, Philips, Siemens Off-label use of Definity for assessment of myocardial
More informationand Treatment in Emergency Care) Trial: Intravenous Glucose, Insulin & Potassium (GIK) in Emergency Medical Services
Results of the IMMEDIATE (Immediate Myocardial Metabolic Enhancement DuringInitial Assessment and Treatment in Emergency Care) Trial: A Double Blinded Randomized Controlled Trial of Intravenous Glucose,
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationWhy Cardiac MRI? Presented by:
Why Cardiac MRI? Presented by: Lisa G. Carkner, MD, FACC 1 Disclosures I have no financial disclosures Objectives Review basic principles of Cardiac MRI. What patient characteristics do I need to consider
More informationStress Echo in viability estimation of patients with ischemic heart disease and low LVEF. Prognostic implications.
Stress Echo in viability estimation of patients with ischemic heart disease and low LVEF. Prognostic implications. Stefanos Karagiannis MD PhD Cardiologist Director Echocardiology Dept ATHENS MEDICAL CENTER
More informationDiagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta
Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations
More informationMyocardial viability testing. What we knew and what is new
Myocardial viability testing. What we knew and what is new Dr B K S Sastry, MD, DM. CARE Hospitals, Hyderabad What is Viability Viability Dysfunctional myocardium subtended by diseased coronary arteries
More informationΔυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ;
Ελληνική Καρδιολογική Εταιρεία Σεμινάρια ομάδων εργασίας Θεσσαλονίκη, 8-10 Φεβρουαρίου 2018 Ομάδα εργασίας Ηχωκαρδιολογίας Δυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ; ΑΓΑΘΗ-ΡΟΖΑ
More informationTranscoronary Infusion of Cardiac Progenitor Cells in Hypoplastic Left Heart Syndrome: 3-year Follow-up of the TICAP Trial
Transcoronary Infusion of Cardiac Progenitor Cells in Hypoplastic Left Heart Syndrome: 3-year Follow-up of the TICAP Trial Shunji Sano, Shuta Ishigami, Takuya Goto, Daiki Ousaka, Suguru Tarui, Michihiro
More informationHeart 101. Objectives. Types of Heart Failure How common is HF? Sign/Symptoms, when to see a doctor? Diagnostic testing
EXAMING HEART FAILURE: HOW TO RECOGNIZE AND TREAT THE WEAK HEART What is Heart Failure? Treatment of Heart Failure End Stage Heart Failure Munir S. Janmohamed M.D. FACC Assistant Clinical Professor of
More informationThe Jay Cohn Lecture 2012: Therapeutic regeneration of the injured heart
The Jay Cohn Lecture 2012: Therapeutic regeneration of the injured heart Eduardo Marbán, M.D., Ph.D. Director, Cedars-Sinai Heart Institute Los Angeles, CA Disclosure: founder & stockholder, Capricor Inc.
More informationImaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD
Imaging in Heart Failure: A Multimodality Approach Thomas Ryan, MD Heart Failure HFrEF HFpEF EF50% Lifetime risk 20% Prevalence 6M Americans Societal costs - $30B 50% 5-year survival 1 Systolic
More informationOld and new insights into viability:perfusion and Perfusion Reserve
Old and new insights into viability:perfusion and Perfusion Reserve R.Senior Professor of Clinical Cardiology Consultant Cardiologist and Director of Echo,Royal Brompton Hospital,London and Northwick Park
More informationA New Method to Rapidly Evaluate LVEF from a Contractility Polar Map. Lebeau et al.
A New Method to Rapidly Evaluate LVEF from a Contractility Polar Map Lebeau et al. Good afternoon It is my pleasure to present to you a new method to rapidly evaluate LVEF from a contractility polar map
More informationGated blood pool ventriculography: Is there still a role in myocardial viability?
Gated blood pool ventriculography: Is there still a role in myocardial viability? Oliver C. Alix, MD Adult Clinical and Nuclear Cardiology St. Luke s Medical Centre - Global City Case Presentation A 62-year-old
More informationSevere Hypertension. Pre-referral considerations: 1. BP of arm and Leg 2. Ambulatory BP 3. Renal causes
Severe Hypertension *Prior to making a referral, call office or Doc Halo, to speak with a Cardiologist or APP to discuss patient and possible treatment options. Please only contact the patient's cardiologist.
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationJ. Schwitter, MD, FESC Section of Cardiology
J. Schwitter, MD, FESC Section of Cardiology CMR Center of the CHUV University Hospital Lausanne - CHUV Switzerland Centre de RM Cardiaque J. Schwitter, MD, FESC Section of Cardiology CMR Center of the
More informationCardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures?
Keenan Research Centre Li Ka Shing Knowledge Institute Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures? Howard Leong-Poi, MD, FRCPC Associate Professor of Medicine St.
More informationCoronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable?
Coronary Revascularization for Severe LV Dysfunction Is s Is the concept of viability testing still viable? Banff 2017 2015 MFMER 3492638-7 Prognosis of Patients With LV Dysfunction and CAD Major determinants
More informationPrognostic Value of Left Ventricular Dyssynchrony by Phase Analysis of Gated SPECT in Patients Undergoing Myocardial Perfusion Imaging
Prognostic Value of Left Ventricular Dyssynchrony by Phase Analysis of Gated SPECT in Patients Undergoing Myocardial Perfusion Imaging Nili Zafrir, Tamir Bental, Ariel Gutstein, Israel Mats, Doron Belzer,
More informationViability Testing Using Dynamic Echocardiography
Viability Testing Using Dynamic Echocardiography Theodora A Zaglavara, MD, PhD Director of Echocardiography EUROMEDICA KYANOUS STAVROS HOSPITAL Thessaloniki GREECE Goals of Cardiac Imaging in Coronary
More informationORIGINAL. Keywords : multidetector-row computed tomography, myocardial infarction, cardiac function
ORIGINAL Department of Digestive and Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan, Faculty of Integrated Art and Sciences, Department
More informationCHRONIC CAD DIAGNOSIS
CHRONIC CAD DIAGNOSIS Chest Pain Evaluation 1. Approach to diagnosis of CAD 2. Classification of chest pain 3. Pre-test likelihood CAD 4. Algorithm for chest pain evaluation in women 5. Indications for
More informationDetection and Assessment of MI: Use of Imaging Methods. Robert O. Bonow, M.D.
Detection and Assessment of MI: Use of Imaging Methods Robert O. Bonow, M.D. Detection and Assessment of MI: Use of Imaging Methods Robert O. Bonow, M.D. No Relationships to Disclose Expert Consensus Document
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationWhen is strain assessment mandatory?
When is strain assessment mandatory? Geneviève Derumeaux University of Lyon France Presenter Disclosure Information Geneviève Derumeaux When is strain assessment mandatory? DISCLOSURE INFORMATION: None
More informationSelective Cardiac Myosin Activators in Heart Failure
Selective Cardiac Myosin Activators in Heart Failure John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationRole of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이
Role of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이 Outline Evaluation of Chest pain Evaluation of MI complications Prediction of Outcomes Evaluation of Chest pain Evaluation
More informationUsefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity
Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity G.D.Aquaro, MD Fondazione G.Monasterio Regione Toscana/CNR Pisa, Italy
More informationDisclosure of Interests. No financial relationships to disclose concerning the content of this presentation or session.
Comparison of Free Breathing Cardiac MRI Radial Technique to the Standard Multi Breath-Hold Cine SSFP CMR Technique For the Assessment of LV Volumes and Function Shimon Kolker, Giora Weisz, Naama Bogot,
More informationBEDSIDE ASSESSMENT OF PATIENTS WITH STEMI
BEDSIDE ASSESSMENT OF PATIENTS WITH STEMI Prof. Maria Dorobantu, PhD, FESC, FACC Emergency Hospital of Bucharest, Romania Presenter Disclosures There are no conflicts/ grants/ disclosures for this presentation.
More informationImpaired Regional Myocardial Function Detection Using the Standard Inter-Segmental Integration SINE Wave Curve On Magnetic Resonance Imaging
Original Article Impaired Regional Myocardial Function Detection Using the Standard Inter-Segmental Integration Ngam-Maung B, RT email : chaothawee@yahoo.com Busakol Ngam-Maung, RT 1 Lertlak Chaothawee,
More informationVelocity Vector Imaging as a new approach for cardiac magnetic resonance: Comparison with echocardiography
Velocity Vector Imaging as a new approach for cardiac magnetic resonance: Comparison with echocardiography Toshinari Onishi 1, Samir K. Saha 2, Daniel Ludwig 1, Erik B. Schelbert 1, David Schwartzman 1,
More informationCardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute
Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute 62 year old male Anterior STEMI late presentation, occluded
More informationMyocardial Strain Imaging in Cardiac Diseases and Cardiomyopathies.
Myocardial Strain Imaging in Cardiac Diseases and Cardiomyopathies. Session: Cardiomyopathy Tarun Pandey MD, FRCR. Associate Professor University of Arkansas for Medical Sciences Disclosures No relevant
More informationعلم االنسان ما لم يعلم
In the name of Allah, the Beneficiate, the Merciful ق ال هللا تعالي: 5 الدى علم بالق لم 4 علم االنسان ما لم يعلم سورة العلق It is He (Allah), Who has taught by the pen He has taught man which he did not
More informationLV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION
LV FUNCTION ASSESSMENT: WHAT IS BEYOND EJECTION FRACTION Jamilah S AlRahimi Assistant Professor, KSU-HS Consultant Noninvasive Cardiology KFCC, MNGHA-WR Introduction LV function assessment in Heart Failure:
More informationImaging in Ischemic Heart Disease: Role of Cardiac MRI
Imaging in Ischemic Heart Disease: Role of Cardiac MRI Chiara Bucciarelli Ducci MD, PhD, FESC, FRCP Consultant Senior Lecturer Cardiologist Bristol Heart Institute, University of Bristol, UK Chair elect,
More informationMultimodality Imaging in Cardiac Stem Cell Research
Multimodality Imaging in Cardiac Stem Cell Research IL SUK SOHN, MD, PhD Department of Cardiology Kyung Hee University Hospital at Gangdong Kyung Hee University School of Medicine, Seoul, Korea Stem Cell
More informationCT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea
CT for Myocardial Characterization of Cardiomyopathy Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea Cardiomyopathy Elliott P et al. Eur Heart J 2008;29:270-276 The European Society
More information2019 Qualified Clinical Data Registry (QCDR) Performance Measures
2019 Qualified Clinical Data Registry (QCDR) Performance Measures Description: This document contains the 18 performance measures approved by CMS for inclusion in the 2019 Qualified Clinical Data Registry
More informationManaging Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology
Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation
More informationCardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018
Cardiac MRI: Detection of Ischemia Cardiac MRI in Today s Clinical Practice Foundations of Cardiovascular Magnetic Resonance Daniel C. Lee, MD, MSc Assistant Professor of Medicine and Radiology Co-Director,
More informationThe Value of Stress MRI in Evaluation of Myocardial Ischemia
The Value of Stress MRI in Evaluation of Myocardial Ischemia Dr. Saeed Al Sayari, MBBS, EBCR, MBA Department of Radiology and Nuclear Medicine Mafraq Hospital, Abu Dhabi United Arab Emirates Introduction
More informationALTERNATIVE APPROACH FOR END-STAGED ISCHEMIC CARDIOMYOPATHY WITH LV ANEURYSM COMBINING SURGICAL AND CELL THERAPY THESSALONIKI, 2018
ALTERNATIVE APPROACH FOR END-STAGED ISCHEMIC CARDIOMYOPATHY WITH LV ANEURYSM COMBINING SURGICAL AND CELL THERAPY THESSALONIKI, 2018 Kostas Katsavrias Sotirios N. Prapas A Cardiac Surgery Dpt Henry Dunant
More informationOTHER NON-CARDIAC USES OF Tc-99m CARDIAC AGENTS Tc-99m Sestamibi for parathyroid imaging, breast tumor imaging, and imaging of other malignant tumors.
DEFINITION OF CARDIAC RADIOPHARMACEUTICAL: A radioactive drug which, when administered for purpose of diagnosis of heart disease, typically elicits no physiological response from the patient. Even though
More informationDOWNLOAD PDF MYOCARDIAL CONTRAST TWO DIMENSIONAL ECHOCARDIOGRAPHY (DEVELOPMENTS IN CARDIOVASCULAR MEDICINE)
Chapter 1 : Imaging Cardiovascular Medicine Stanford Medicine contrast two-dimensional echocardiography (MC-2DE), a new and exciting diagnostic methodology for assessment of myocardial perfusion, which
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationAn Update in Heart Failure
An Update in Heart Failure Dr Peter Dias Cardiologist Heartswest AHFCTS Fiona Stanley Hospital Disclosures No financial, industry, pharma disclosures I am not an endocrinologist References Heart disease
More information2/2/2011. Strain and Strain Rate Imaging How, Why and When? Movement vs Deformation. Doppler Myocardial Velocities. Movement. Deformation.
Strain and Strain Rate Imaging How, Why and When? João L. Cavalcante, MD Advanced Cardiac Imaging Fellow Cleveland Clinic Foundation Disclosures: No conflicts of interest Movement vs Deformation Movement
More informationAbnormal, Autoquant Adenosine Myocardial Perfusion Heart Imaging. ID: GOLD Date: Age: 46 Sex: M John Doe Phone (310)
Background: Reason: preoperative assessment of CAD, Shortness of Breath Symptom: atypical chest pain Risk factors: hypertension Under influence: a beta blocker Medications: digoxin Height: 66 in. Weight:
More informationRevascularization In HFrEF: Are We Close To The Truth. Ali Almasood
Revascularization In HFrEF: Are We Close To The Truth Ali Almasood HF epidemic 1-2% of the population have HF At least one-half have heart failure with reduced ejection fraction (HF- REF) The most common
More informationEjection Fraction in Heart Failure: A Redefinition. Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA
Ejection Fraction in Heart Failure: A Redefinition Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA Word of caution!!! Incomplete understanding of a disease process may lead to
More information411.1 INTERMED CORONARY SYNDROME 412 OLD MYOCARDIAL INFARCT ANGINA PECTORIS OT/UNSPEC CORONARY ATHRSCL UNS VESSEL
78451 Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative NUC 1073 410.91 AMI UNSP INITIAL EPISODE 410.92 AMI UNSP SUBSEQUENT EPISODE 414.8 CHR ISCHEMIC HRT
More informationAvailable online at ScienceDirect. Procedia Engineering 126 (2015 )
Available online at www.sciencedirect.com ScienceDirect Procedia Engineering 126 (2015 ) 441 445 7th International Conference on Fluid Mechanics, ICFM7 FSI modeling approach to develop right ventricle
More informationPVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.
PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. Cardiologist and Electrophysiologist No conflict of interest related to this presentation Objectives 1. PVCs are benign. What is the Evidence?
More informationManagement of High-Risk CAD : Surgeons Perspective
Management of High-Risk CAD : Surgeons Perspective Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Conflict : Cardiac Surgeon! High Risk CABG 77 year old with prior large anterior
More informationAssessment Of Myocardial Viability
Assessment Of Myocardial Viability James K. Min, MD FACC President, Society of Cardiovascular Computed Tomography Associate Professor of Medicine, UCLA School of Medicine Associate Professor of Medicine
More informationThe use of Cardiac CT and MRI in Clinical Practice
The use of Cardiac CT and MRI in Clinical Practice Matthew W. Martinez, MD Assistant Professor of Medicine LVPG - Lehigh Valley Heart Specialists Lehigh Valley Health Network Oct. 3, 2009 DISCLOSURE Relevant
More informationWhat the Cardiologist needs to know from Medical Images
What the Cardiologist needs to know from Medical Images Gerald Maurer Department of Cardiology Medical University of Vienna What kinds of Cardiologists Plumbers Electricians Photographers And then there
More informationQualitative and Quantitative Assessment of Perfusion
APCDE 2011 Qualitative and Quantitative Assessment of Perfusion Hyun Ju Yoon Chonnam National University Hospital Gwangju, Korea ISCHEMIC CASCADE Blood flow mismatch Perfusion defects on nuclear imaging,
More information